

Asthma Management by Appropriate Controller Medications (2014)

Benchmark to qualify for bonus payments: This measurement has separate benchmarks for different age ranges. The bonus will be determined for each age group independently.

- ages 5-11 years benchmarks 90.31 (50th percentile) or 92.92% (75th percentile)
- ages 12-18 years benchmark 85.88% (50th percentile) or 88.99 (75th percentile)
- ages 19-50 years benchmark 74.90% (50th percentile) or 80.69% (75th percentile)
- ages 51-64 years benchmark 72.66% (50th percentile) or 77.95% (75th percentile)

Measurement Period: Calendar year 2014

Qualifying Service: One pharmacy claim for an Asthma Controller Medication (see Table: Asthma Controller Medication). Writing a prescription is not a qualifying service. The prescription must be dispensed at least once during the measurement period, based on paid claims data from HFS.

Asthma Controller Medications

Description		Prescriptions	
Antiasthmatic combinations	Dyphylline-guaifenesin	Guaifenesin-theophylline	
Antibody inhibitor	Omalizumab		
Inhaled steroid combinations	Budesonide-formateral	Fluticasone-salmeterol	Mometasone-formateral
Inhaled corticosteroids	BeclomethasoneBudesonideCiclesonide	FlunisolideFluticasone CFC free	Mometasone Triamcinolone
Leukotriene modifiers	Montelukast	 Zafirlukast 	• Zileuton
Mast cell stabilizers	 Cromolyn 		
Methylxanthines	Aminophylline	 Dyphylline 	Theophylline

Qualifying patient: Patients with persistent asthma on the PCPs roster on December 1, 2014. Patients are considered to have persistent asthma if they meet any one of the four criteria below during both the measurement year and the year prior to the measurement year (criteria need not be the same across both years).

- At least one ED visit with asthma as the principal diagnosis.
- At least one inpatient admission with asthma as the principal diagnosis.
- At least four outpatient asthma visits on different dates of service (non-ER service IHC 2014 Bonus Payment Program

with RecordIDC of 'N' or 'O') with asthma as the primary diagnosis and at least two asthma medication dispensing events (see Table: Asthma Medications).

 At least four asthma medication dispensing events, i.e. an asthma medication is dispensed on four occasions (see Table: Asthma Medications).

Asthma Medications

Description		Prescriptions	
Antiasthmatic combinations	Dyphylline-guaifenesin	Guaifenesin-theophylline	
Antibody inhibitor	Omalizumab		
Inhaled steroid combinations	Budesonide-formoterol	Fluticasone-salmeterol	Mometasone-formoterol
Inhaled corticosteroids	Beclomethasone	Flunisolide	Triamoinolone
	Budesonide	 Fluticasone CFC free 	
	Cidesonide	 Mometasone 	
Leukotriene modifiers	 Montelukast 	 Zafirlukast 	• Zileuton
Long-acting, inhaled beta-2 agonists	Arformoterol	Formateral	Salmeterol
Mast cell stabilizers	Cromolyn		
Methylxanthines	Aminophylline	• Dyphylline	Theophylline
Short-acting, inhaled beta-2	Albuterol	Pirbuterol	
agonists	 Levalbuterol 		

For a patient identified as having persistent asthma because of at least four asthma medication dispensing events, where leukotriene modifiers were the sole asthma medication dispensed, the member must:

- Meet any of the three other criteria listed above in the same year as the leukotriene modifier, or
- Have at least one diagnosis of asthma in any setting in the same year as the leukotriene modifier (i.e., measurement year or prior to the measurement year).

Codes to Identify Visit Type

Description	СР	UB-92 Revenue
Outpatient/ Office Visit	99201-99205, 99211-99215,	051-0517, 0519-
	99217-99220, 99241-99245,	0523, 0526-0529,
	99341-99345, 99347-99350,	
	99381-99387, 99391-	0982, 0983
	99397,99401-99404,99411-	
	99412, 99420, 99429, 99455,	
	99456	

In-patient	99238, 99239, 99251-99255, 99291	0100, 0101, 0110-0114, 0119-0124, 0129-0134, 0139-0144, 0149-0154, 0159, 0160, 0164, 0167- 0169, 0200-0214, 0219, 0720-0724, 0729,0987
Emergency	99281-99285	0450-0452, 0456, 0459,
Department		0981

Asthma Diagnosis Codes (ICD-9): 493x

Exclusions:

Emphysema: 492x, 518.1, 518.2

COPD/chronic respiratory conditions due to fumes/vapor: 491.2x, 493.2x, 496, 506.4

Cystic Fibrosis: 277x

Acute Respiratory Failure: 518.81

Reference: http://www.nhlbi.nih.gov/guidelines/asthma/